1-(2-甲基-[3]吡啶基)-乙醇 | 90086-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-(2-甲基-[3]吡啶基)-乙醇
• 英文名称: rac-1-(2-methylpyridin-3-yl)ethan-1-ol
• 英文别名: 1-(2-methyl-[3]pyridyl)-ethanol；1-(2-Methyl-[3]pyridyl)-aethanol；1-(2-Methylpyridin-3-yl)ethan-1-ol；1-(2-methylpyridin-3-yl)ethanol
• CAS: 90086-87-6
• 化学式: C₈H₁₁NO
• 分子量: 137.181
• InChiKey: UGNWYUKGPPJQGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-溴甲基-2-甲基-4-氨基嘧啶溴化氢 、 1-(2-甲基-[3]吡啶基)-乙醇 生成 1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-3-(1-hydroxy-ethyl)-2-methyl-pyridinium; bromide hydrobromide
  参考文献：
  名称：

  Baumgarten; Dornow, Chemische Berichte, 1940, vol. 73, p. 44;353

  摘要：

  DOI：
• 作为产物：
  描述：

  3-乙酰基-2-甲基吡啶 在 乙醇 作用下， 以80%的产率得到1-(2-甲基-[3]吡啶基)-乙醇
  参考文献：
  名称：

  3-乙酰基丙啶的光化学异构化为环鸟苷[ c ]吡啶，涉及诺里尔II型反应

  摘要：

  3-乙酰基-2-烷氧基-4,6-二甲基吡啶的光解产生环丁烯醇，2-烷氧基-3,6-二甲基-3-羟基-环丁[ c ]吡啶，通过Norrish II型环化获得高收率，而3-乙酰基-2-甲基吡啶不环化成环丁烯醇。

  DOI：

  10.1039/c39930001023

文献信息

• [EN] TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF<br/>[FR] PYRIDYLSULFONAMIDES DE CARBAMATE DE TRIAZOLE UTILISÉES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LPA ET LEURS UTILISATIONS
  申请人：GILEAD SCIENCES INC

  公开号：WO2021097039A1

  公开（公告）日：2021-05-20

  The present disclosure relates generally to compounds of Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

  本公开涉及通常与结合到溶酶磷脂酸受体1（LPAR1）并作为LPAR1拮抗剂的化合物的公式（I）有关。本公开进一步涉及利用这些化合物制备药物治疗通过结合LPAR1引起的疾病和/或病况，包括纤维化和肝病，如非酒精性脂肪性肝炎（NASH）。
• Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists
  申请人：Chambers Stuart Mark

  公开号：US20070281952A1

  公开（公告）日：2007-12-06

  Compounds of formula (I) are potent and selective 5-HT 2A antagonists, useful in treatment of a variety of adverse conditions of the CNS.

  公式为（I）的化合物是有效且选择性的5-HT2A拮抗剂，可用于治疗中枢神经系统的各种不良状况。
• DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS
  申请人：YAMASHITA Hiroshi

  公开号：US20120028920A1

  公开（公告）日：2012-02-02

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种由式（1）所表示的杂环化合物或其盐：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的光谱，包括中枢神经系统障碍，无副作用且安全性高。
• TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE
  申请人：NewGen Therapeutics, Inc.

  公开号：US20140221314A1

  公开（公告）日：2014-08-07

  The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.

  本发明提供了包含含磷三环化合物的组合物，包括邻苯二酮-1(2H)-酮衍生物。这些化合物是聚(ADP-核糖)聚合酶(PARP)的有效抑制剂，特别是PARP-1和潜在的PARP-2。它们还表现出良好的细胞活性，能够抑制聚(ADP-核糖)寡聚体形成。这些化合物可用作单一治疗或与其他治疗药物联合使用，治疗PARP参与的疾病，如癌症、炎症性疾病和缺血性疾病。因此，本发明还提供了一种治疗PARP参与的疾病的方法，包括向需要的个体施用本发明化合物的有效量。
• 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS
  申请人：KUDUK Scott D.

  公开号：US20160102073A1

  公开（公告）日：2016-04-14

  The present invention is directed to 2-hydroxymethyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-羟甲基化合物，它们是促进睡眠的药物受体拮抗剂。本发明还涉及上述化合物在潜在的神经和精神障碍和疾病的治疗或预防中的用途，其中促进睡眠的药物受体参与其中。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗促进睡眠的药物受体参与的疾病中的用途。